---
title: "Market Engagement for Onasemnogene Abeparvovec (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service"
ocid: "ocds-h6vhtk-060244"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-060244"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-060244.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-060244.json"
source: "Find A Tender Service"
current_stage: "Planning"
buyer: "NHS ENGLAND"
published: "2026-01-08"
---

# Market Engagement for Onasemnogene Abeparvovec (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

Buyer: NHS ENGLAND  
Current stage: Planning  
OCID: ocds-h6vhtk-060244

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-060244)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-060244.json)

## Summary

The procurement process, led by NHS England, is currently in the planning stage and focuses on the title "Market Engagement for Onasemnogene Abeparvovec (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service." This initiative falls under the health services industry category and aims to gather market feedback on the delivery capabilities for these gene therapy services. Located in the UK, this exercise is designed to identify interest and capacity in the market, which will inform the commissioning approach. The closing date for submitting market engagement responses is set for 12:00 pm (noon) on 2nd February 2026, and any future notices are anticipated on 12th March 2026.

This tender offers significant opportunities for businesses specialising in rare disease treatments, particularly those with expertise in gene therapy. Companies with capabilities in health services delivery or those considering forming consortia to enhance service provision will find this engagement a strategic opportunity for business growth. The procurement method prioritises direct engagement and comprehensive feedback, which will influence the commissioning strategy. SMEs, large healthcare providers, and organisations in the life sciences sector could leverage this market engagement to gain insights, influence service design, and potentially secure future contracts. Enquiries can be directed to the contact provided, Surinder Kahlon, or through the Atamis e-sourcing portal indicated in the process documentation.

## Notice

The key objective of the Market Engagement Exercise is to seek feedback from the market regarding levels of interest, capability and capacity in relation to delivering the onasemnogene abeparvovec (zolgensma(r)) service and the onasemnogene abeparvovec intrathecal (OAV101 IT) service

### Lot Information

Lot 1

The key objective of the Market Engagement Exercise is to seek feedback from the market regarding levels of interest, capability and capacity in relation to delivering the onasemnogene abeparvovec (zolgensma(r)) service and the onasemnogene abeparvovec intrathecal (OAV101 IT) service.

The commissioner isinterested in receiving feedback from the market on their capability and capacity to deliver services for zolgensma(r) or combined (zolgensma(r) and OAV101 IT).

It is also anticipated that the findings from this market engagement exercise will assist in the decision-making for the approach to commissioning the Service(s).

If, as a result of the market engagement, competition is absent or minimal, in any of the potential Lots/Regions, the Commissioner may use the Most Suitable Provider Process or Direct Award Process C. Where competition is absent, Direct Award Process A may be utilised. If, as a result of the market engagement, competition is apparent in a potential Lot/Region , a Competitive Process may be undertaken to award the contract for that Lot.

Service Summary:
Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. The severity of SMA can vary greatly between individuals. Historically, the condition has been classified into different types, determined by clinicians at the time of diagnosis. This classification is based on both the age at which symptoms first appear, and the highest level of motor function achieved by the patient. 

The types range from type 0, the most severe form, where symptoms are present before birth and most affected infants don't survive past 6 months, through to type 4, which develops in adulthood and is associated with mild motor impairment and a normal life span. However, because the disease presents so variably, consistently categorising patients into these types at the point of diagnosis can be challenging.
Onasemnogene abeparvovec (zolgensma(r)) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabling production of sufficient amounts of SMN. It is administered intravenously.

Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time gene therapy for patients with SMA, proposed to treat people with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct population from the indication for Zolgensma(r). 

Following market engagement and review of capable providers, the Commissioner will consider the most appropriate PSR process(es) to formally commission each service. Interested parties may respond to this Market Engagement Exercise in partnership with other organisations as part of a consortium, subject to them appointing a consortium lead to act on their behalf as the lead contracting party would take overall responsibility for delivery of the service(s) in accordance with the requirements of any future contract(s) if successful.

To express interest and participate in the Market Engagement Exercise, please register and apply via Atamis esourcing portal https://health-family.force.com/s/Welcome 
Should Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at:
Phone: 08000988201
E-mail: support-health@atamis.co.uk
The closing date for completed Market Engagement responses is 12:00pm (noon), on Monday 2nd February 2026.
Atamis Project reference C410884.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/001628-2026 |
| Notice type | Planning Notice |
| Procurement type | Standard |
| Procurement category | Services |
| Procurement method | Not Specified |
| Procurement method details | Not specified |
| Tender suitability | Not specified |
| Awardee scale | Not specified |
| All stages | Planning |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 8 Jan 2026 |
| Submission deadline | Not specified |
| Future notice date | 12 Mar 2026 |
| Award date | Not specified |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | Not specified |

## Status

| Field | Value |
| --- | --- |
| Tender status | Planned |
| Lots status | Planned |
| Awards status | Not specified |
| Contracts status | Not specified |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS ENGLAND |
| Locality | LONDON |
| Post town | South East London |
| Postcode | SE1 8UG |
| Country | England |
| ITL 1 | TLI London |
| ITL 2 | TLI4 Inner London - East |
| ITL 3 | TLI45 Lambeth |
| Local authority | Lambeth |
| Electoral ward | Waterloo & South Bank |
| Westminster constituency | Vauxhall and Camberwell Green |
| Delivery location | Not specified |

## CPV Codes

### Divisions

- 85 - Health and social work services

### Codes

- 85100000 - Health services

## Release History

- 8 Jan 2026 at 17:02 - Planning - Planning Notice - https://www.find-tender.service.gov.uk/Notice/001628-2026

## Notice URLs

- https://atamis-1928.my.site.com/s/Welcome
- https://health-family.force.com/s/Welcome
- https://www.ardengemcsu.nhs.uk/
- https://www.england.nhs.uk/

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-060244. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-060244.json.